Skip to main content
Caplight Logo









pacDNA

pacDNA

Private
Cambridge, MassachusettsHealthcare & Life Scienceshttps://pacdna.com

Last Round

Grant

Jan 17, 2025

Total Funding Raised

$2.99M

Company Overview

pacDNA operates in Healthcare & Life Sciences and is based in Cambridge, Massachusetts. Its latest recorded funding round was a Grant round in January 2025.

pacDNA is a biotechnology company that develops oligonucleotide therapeutics for the treatment of cancer and rare genetic disorders.

Sector

Healthcare & Life Sciences

Verticals

Biotechnology, Drug Discovery

Business Model

B2B

Customer Profile

Revenue Share, Services & Consulting, Government Contracts

AI Layer

Non-AI

Historical Pricing

Historical view of private secondary pricing and transaction trends.

Pricing history

Caplight clients see full MarketPrice™ history and secondary transactions.

Book a demo

For institutional investors. Book with your work email.

Caplight Momentum Score

Proprietary index based on bid/ask volume and sentiment.

Momentum history

Caplight clients track how buyer interest and sentiment change over time.

Book a demo

For institutional investors. Book with your work email.

pacDNA Comparables

Compare pacDNA with similar companies based on industry and business-model similarity.

pacDNA comparables — related companies by embedding similarity
CompanySimilarityMarket Cap
Entos Pharmaceuticals
75%
PepGen
72%
Avidity Biosciences
68%
Book a demo to see all comparables

For institutional investors. Book with your work email.

pacDNA Funding Rounds

Historical fundraising activity

Data table
RoundDateAmount RaisedValuationInvestorsSources
GrantJan 17, 2025
GrantSep 1, 2023
GrantDec 1, 2022
AcceleratorSep 1, 2022
GrantJul 1, 2022
Book a demo to see all funding rounds

For institutional investors. Book with your work email.

pacDNA Investors

Notable investors and investment history

Market signals

Structured signals derived from secondary market and firmographic data.

  • Jan 17, 2025

    $490K grant from Congressionally Directed Medical Research Programs

  • Sep 1, 2023

    $50K grant received from Northeastern University Center for Research Innovation.

Book a demo to see all signals

For institutional investors. Book with your work email.

pacDNA Filings

Explore SEC and related filing metadata, where available.

pacDNA filings preview — column headings only; records require access
TypeDateAmount OfferedAmount SoldFilingPagesDownload

Filing documents are not displayed on this public page. Request access to learn about available coverage.

Book a demo

For institutional investors. Book with your work email.

Frequently Asked Questions

Common questions about pacDNA's valuation, stock price, and market status.

Is pacDNA a public or private company?

pacDNA is a private company.

What is the current stock price of pacDNA?

pacDNA is a private company, so its shares have no public market price. Caplight tracks pacDNA's secondary market activity and provides MarketPrice™ estimates of its share price to Caplight users.

How much is pacDNA worth (valuation)?

Valuation information for pacDNA is not publicly available.

Can I buy pacDNA stock?

pacDNA shares may be available on secondary markets subject to transfer restrictions. Caplight facilitates secondary market transactions for accredited investors.

When was pacDNA's last funding round?

pacDNA's most recent funding round was Grant on January 17, 2025.

Who are the main investors in pacDNA?

Key investors in pacDNA include NIH RADx, Congressionally Directed Medical Research Programs, Northeastern University Center for Research Innovation.

Will pacDNA IPO soon?

No public IPO plans have been announced for pacDNA.

How can I track pacDNA secondary market activity?

Caplight tracks bids, offers, and trades in pacDNA's shares on secondary markets.

Firmographic Details

HeadquartersCambridge, Massachusetts
Year Founded2023
Last FundingJan 17, 2025

Institutional Data Access

Join leading institutional investors using Caplight to access private market data, discover pricing, and execute secondary block trades.

Book a demo

For institutional investors. Book with your work email.

See something wrong or outdated?